Collaborative Network for Generating Scientific Evidence in COVID-19 For the Unified Health System in Brazil - RECOVER SUS-BRASIL (Recoversus)
Rede Colaborativa Para Geração de Evidência Científica em COVID-19 Para o Sistema Único de Saúde no Brasil - RECOVER SUS-BRASIL
研究概览
详细说明
Study 1 procedures are clinical and sociodemographic data collected through interview at admission and results of complementary exams performed during hospitalization. Data will be collected during the participant's inclusion visit (Day 0,equivalent to the date of hospital admission) and subsequently according to in-hospital visits untill discharge moment.
The team of researchers will have access to the electronic medical record or, as the case, to the paper medical record for the collection of data and variables of the study interest, and questionnaires with specific questions from participants or family members.
A visit in 31-60 days will be made, by telephone contact, for the application by a health professional of a questionnaire on mental health and verification of the occurrence of death or hospital readmission. The mental health questionnaire includes tracking disorders, such as: depression, anxiety, post-traumatic stress disorder, suicidal ideation and insomnia [questionnaires PHQ-9, GAD-7, Abbreviated PCL-C and Index Severity of Insomnia], in addition to a questionnaire on social support [MSPSS]. Patients identified with health disorders over the telephone will be referred to specialized care by a psychiatrist. Study 2 - Data from information systems drug dispensation (SICLOM - http://www.aids.gov.br/pt-br/gestores/sistemas-de-informacao/sistema-de-controle-logistico-demedicamentos-siclom), laboratory tests (SISCEL - http : //www.aids.gov.br/pt-br/sistema-de-informacao/sistema-de-controle-de-exameslaboratoriais-da-rede-nacional-de-contagem-de), information on mortality (SIM - http://sim.saude.gov.br/) and COVID-19 case notification database will be released to the Ministry of Health, with data identified with patient name, mother's name and date of birth to enable the linkage process. This sensitive data is obtained through specific forms, which include confidentiality clauses of the data. All transport and storage of this data, whether by digital physical means (for example, CD) or via the web, will be done in encrypted form with a strong algorithm. The final database will be de-identified to guarantee the confidentiality of the participants.
研究类型
注册 (预期的)
联系人和位置
学习地点
-
-
-
São Paulo、巴西、01246-900
- Instituto de Infectologia Emilio Ribas
-
-
Bahia
-
Salvador、Bahia、巴西、41332-150
- Hospital Couto Maia/SES/BA
-
-
Ceará
-
Fortaleza、Ceará、巴西、60455-610
- Hospital São José de Doenças Infecciosas - HSJ / Secretaria de Saúde Fortaleza
-
-
Minas Gerais
-
Belo Horizonte、Minas Gerais、巴西、31270-901
- Universidade Federal de Minas Gerais
-
-
RJ
-
Rio de Janeiro、RJ、巴西、21040-360
- Instituto Nacional de Infectologia Evandro Chagas (Fiocruz)
-
Rio de Janeiro、RJ、巴西、20221-161
- Hospital dos Servidores do Estado/RJ
-
Rio de Janeiro、RJ、巴西、20270-004
- Hospital Universitário Gaffree e Guinle/HUGG/UNIRIO
-
Rio de Janeiro、RJ、巴西、20551-030
- Hospital Universitário Pedro Ernesto/UERJ
-
Rio de Janeiro、RJ、巴西、21941-617
- Universidade Federal do Rio de Janeiro
-
-
Rio Grande Do Sul
-
Porto Alegre、Rio Grande Do Sul、巴西
- Hospital Nossa Senhora da Conceicao
-
Santa Maria、Rio Grande Do Sul、巴西、97105-900
- Universidade Federal de Santa Maria/ Pró-Reitoria de PósGraduação e Pesquisa
-
-
Santa Catarina
-
São José、Santa Catarina、巴西、88103-310
- Hospital Regional de São José
-
-
São Paulo
-
Sumaré、São Paulo、巴西、13174-530
- Hospital Estadual Sumaré Dr. Leandro Francheschini
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:Adults aged 18 years. Hospitalized for suspicious signs and symptoms of COVID-19 infection by the medical care team or confirmed by laboratory tests such as RT-PCR or rapid tests.
Exclusion Criteria:Patient or family member refusal
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
---|---|
Total participants
3500 participants that will have their medical forms checked
|
Clinical and sociodemographic data collected through interview at admission and results of complementary tests performed during hospitalization.
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
The main outcome of the study is hospital mortality
大体时间:25/05/2021
|
25/05/2021
|
次要结果测量
结果测量 |
大体时间 |
---|---|
Length of hospital stay
大体时间:25/05/2021
|
25/05/2021
|
合作者和调查者
合作者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
新冠肺炎的临床试验
-
Texas Woman's UniversityNational Institutes of Health (NIH)尚未招聘COVID19测试
-
Aarhus University HospitalUniversity of Aarhus; Pharma Nord完全的
-
Diffusion Pharmaceuticals Inc完全的
-
Lumos DiagnosticsRapid Pathogen Screening完全的
-
Cairo UniversityKasr El Aini Hospital未知
-
Assistance Publique - Hôpitaux de Paris未知
Data collection的临床试验
-
Cliniques universitaires Saint-Luc- Université...Université de Liège招聘中
-
Steno Diabetes Center CopenhagenUniversity of Southern Denmark; Steno Diabetes Center Sjaelland主动,不招人